Claims for Patent: 6,344,479
✉ Email this page to a colleague
Summary for Patent: 6,344,479
| Title: | Method of preventing retinopathy of prematurity in a neonate |
| Abstract: | A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate. |
| Inventor(s): | Van Overmeire; Bart (Antwerp, BE), Darko; Laszlo (Westport, CT) |
| Assignee: | Farmacon-Il, LLC (Westport, CT) |
| Application Number: | 09/813,280 |
| Patent Claims: |
1. A method of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of
parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation and
stimulate normal retinal development and retinal vascularity in said neonate.
2. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is a salt of a basic amino acid. 3. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is ibuprofen lysinate or ibuprofen arginate. 4. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the L-isomer. 5. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the racemate. 6. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered by intravenous, subcutaneous or intramuscular injection. 7. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a daily dosage of 1 to 20 mg based on ibuprofen content. 8. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a concentration of 1 to 20 mg/ml in a vehicle acceptable for injection. 9. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered to the prematurely born neonate during the first month of life. 10. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered once a day for 3 days in respective daily doses of about 10 mg, 5 mg and 5 mg per kg of body weight and the administration may be repeated. |
